共 50 条
- [1] Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus studyMOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)Schram, Alison M.Subbiah, VivekLiao, Chih-YiMoreno, VictorDesamparados, RodaPonz-Sarvise, MarianoDotan, EfratCassier, Philippe AlexandreMoreno, IreneVarkaris, AndreasKim, Richard D.Garralda, ElenaOpdam, FransTai, DavidItaliano, AntoineOh, Do-YounGoyal, LipikaFontana, EliseLiu, JiaBoukovala, MyrtoGhiringelli, FrancoisBorad, Mitesh J.Babiker, HaniJin, ZhaohuiMillward, MichaelYachnin, JeffreyKamath, Suneel DeepakCoward, Jermaine M.Yoo, ChanghoonKelley, Robin KateSahai, VaibhavBridgewater, JohnSpringfield, ChristophFlorou, VaiaEl-Khoueiry, AnthonyEskens, FerryLin, BrucePaulson, ScottCurigliano, GiuseppeMurphy, MeredithDeary, AliciaRicard, FabienJen, Kai YuRamirez, FlorenceBlakesley, Rick E.Schmidt-Kittler, OlegMar, Brenton G.Park, Joon OhHollebecque, Antoine
- [2] First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumorsANNALS OF ONCOLOGY, 2021, 32 : S120 - S120Goyal, L.Subbiah, V.Mahipal, A.Kamath, S.Mody, K.Borad, M.El-Khoueiry, A.Sahai, V.Kim, R.Kelley, R.Schmidt-Kittler, O.Shen, J.Jen, K.Deary, A.Padval, M.Sherwin, C.Wolf, B.Schram, A.
- [3] First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Schram, Alison M.Kamath, Suneel DeepakEl-Khoueiry, Anthony B.Borad, Mitesh J.Mody, KabirMahipal, AmitGoyal, LipikaSahai, VaibhavSchmidt-Kittler, OlegShen, JinshanJen, Kai YuDeary, AliciaSherwin, Cori AnnPadval, MaheshWolf, Beni B.Subbiah, Vivek
- [4] Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Borad, Mitesh J.Schram, Alison M.Kim, Richard D.Kamath, Suneel DeepakSahai, VaibhavDotan, EfratKelley, Robin KatePonz-Sarvise, MarianoOh, Do-YounYachnin, JeffreyFlorou, VaiaCassier, Philippe AlexandrePark, Joon OhLiao, Chih-YiMillward, MichaelRamirez, FlorenceRicard, Fabien JeanHollebecque, AntoineSubbiah, VivekGoyal, Lipika
- [5] RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsCANCER DISCOVERY, 2023, 13 (09) : 2012 - 2031Subbiah, VivekSahai, VaibhavMaglic, DejanBruderek, KamilToure, B. BarryZhao, SongpingValverde, RobertoO'Hearn, Patrick J.Moustakas, Demetri T.Schoenherr, HeikeGerami-Moayed, NastaranTaylor, Alexander M.Hudson, Brandi M.Houde, Damian J.Pal, DebjaniFoster, LindseyGunaydin, HakanAyaz, PelinSharon, Dina A.Goyal, LipikaSchram, Alison M.Kamath, SuneelSherwin, Cori AnnSchmidt-Kittler, OlegJen, Kai YuRicard, FabienWolf, Beni B.Shaw, David E.Bergstrom, Donald A.Watters, JamesCasaletto, Jessica B.
- [6] Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (06)Schonherr, HeikeAyaz, PelinTaylor, Alexander M.Casaletto, Jessica B.Toure, B. BarryMoustakas, Demetri T.Hudson, Brandi M.Valverde, RobertoZhao, SongpingO'Hearn, Patrick J.Foster, LindseySharon, Dina A.Garfinkle, SamGiordanetto, FabrizioLescarbeau, AndreKurukulasuriya, RaviGerami-Moayed, NastaranMaglic, DejanBruderek, KamilNaik, GaauriGunaydin, HakanMader, Mary M.Boezio, Alessandro A.McLean, Thomas H.Chen, RongfengWang, YanxiaShaw, David E.Watters, JamesBergstrom, Donald A.
- [7] First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumorsMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Goyal, LipikaBorad, MiteshSubbiah, VivekMahipal, AmitKamath, SuneelMody, KabirKelley, Robin KatieKim, RichardSahai, VaibhavEl-Khoueiry, AnthonyDotan, EfratSchmidt-Kittler, OlegShen, JinshanJen, Kai YuDeary, AliciaGuo, WeiPadval, MaheshSherwin, Cori Ann J.Ferte, CharlesWolf, BeniSchram, Alison M.
- [8] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trialANNALS OF ONCOLOGY, 2022, 33 : S1461 - S1462Park, J. O.Meng, D. T. WaiHollebecque, A.Borad, M.Goyal, L.Schram, A.Cassier, P.Kamath, S. D.Dotan, E.Kim, R.Sahai, V.Liao, C-Y.Millward, M.Roda Perez, D.Blakesley, R.Wolf, B.Subbiah, V.Kelley, R. K.Oh, D-Y.
- [9] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trialANNALS OF ONCOLOGY, 2022, 33 (07) : S1381 - S1381Hollebecque, A.Borad, M.Goyal, L.Schram, A.Park, J. O.Cassier, P. A.Kamath, S. D.Meng, D. T. WaiDotan, E.Kim, R.Sahai, V.Oh, D-Y.Liao, C-Y.Millward, M.Perez, D. RodaFerte, C.Blakesley, R.Wolf, B.Subbiah, V.Kelley, R. K.
- [10] Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitorEUROPEAN JOURNAL OF CANCER, 2022, 174 : S116 - S116Schram, A.Borad, M.Sahai, V.Kamath, S.Kim, R.Liao, C. Y. A.Oh, D. Y.Ponz-Sarvise, M.Yachnin, J.Shell, S. A.Cassier, P.Dotan, E.Florou, V.Moreno, V.Park, J. O.Tai, D.Schmidt-Kittler, O.Ferte, C.Goyal, L.Subbiah, V.